Actavis faces New York antitrust lawsuit over Namenda XR switch
This article was originally published in Scrip
New York Attorney General Eric Schneiderman filed a lawsuit against Actavis to stop the "forced switch" of Alzheimer's disease patients from twice-daily Namenda (memantine) to once-daily Namenda XR several months before generic memantine becomes available in mid-2015.
You may also be interested in...
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.